Clinical Trials
Randomized trial evaluates second-line zolbetuximab in advanced gastric cancer
Inagaki et alESMO Gastrointestinal Oncology

Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), in combination with fluoropyrimidine- and platinum-based chemotherapy, is the established first-line standard of care for patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) cancer following results from the phase III SPOTLIGHT and GLOW trials. However, evidence evaluating the efficacy and safety of continuing CLDN18.2 blockade beyond initial disease progression has not been established. Because CLDN18.2 expression is reported to be maintained after systemic chemotherapy and resistance mechanisms remain undefined, continuing targeted therapy into subsequent lines warrants clinical evaluation.
To address this question, the multicenter, open-label, randomized phase II ZELDA trial (jRCTs071250038) was initiated by the West Japan Oncology Group and the Kyushu Study Group of Clinical Cancer in Japan. The study assesses whether adding zolbetuximab to standard second-line nab-paclitaxel plus ramucirumab prolongs overall survival in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma whose disease progressed during first-line zolbetuximab-containing therapy.
The protocol incorporates an initial safety lead-in phase (n = 6) to verify the tolerability of the triplet combination of zolbetuximab, nab-paclitaxel, and ramucirumab. Following safety confirmation, 210 patients are randomized 1:1 to receive either nab-paclitaxel plus ramucirumab alone (Arm A, control) or zolbetuximab plus nab-paclitaxel and ramucirumab (Arm B, experimental). The primary endpoint is overall survival assessed in the full analysis set. The trial also incorporates integrated translational research (ZELDA-TR) to evaluate associated biomarkers.
Key Takeaways
- Zolbetuximab combined with fluoropyrimidine- and platinum-based chemotherapy is the established first-line standard of care for claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction cancer based on evidence from the phase III SPOTLIGHT and GLOW trials.
Read the original sourceESMO Gastrointestinal Oncology
